Noveris Health Sciences Inc. NVRS
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 109.80% | 6,305.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 120.08% | 6,305.56% | |||
| Operating Income | -120.08% | -6,305.56% | |||
| Income Before Tax | 101.40% | -152.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 101.40% | -152.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 101.40% | -152.00% | |||
| EBIT | -120.08% | -6,305.56% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 100.40% | -104.04% | |||
| Normalized Basic EPS | 97.41% | 68.46% | |||
| EPS Diluted | 100.40% | -104.04% | |||
| Normalized Diluted EPS | 97.41% | 68.46% | |||
| Average Basic Shares Outstanding | 268.88% | 1,185.08% | |||
| Average Diluted Shares Outstanding | 268.88% | 1,185.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||